- NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen iro colaborar no desenvolvimento e comercializao futuros de NRX–101 para tratar [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX–101 for suicidal treatment–resistant bipolar depression (S–TRBD) for global markets
Read more »
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4–RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs
[...] Read more »Two Female Scientists Win this year’s King Faisal Prize
Jeddah, Saudi Arabia, Jan. 04, 2023 (GLOBE NEWSWIRE) — Two women scientists were announced King Faisal Prize for Medicine and Science laureates for 2023: a Covid–19 vaccine developer and a nanotechnology scientist. Six others [...] Read more »
Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases
First in human clinical study provides proof–of–concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate effects of [...] Read more »
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, announced [...] Read more »
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »